Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
  1. Home
  2. Publications
  3. Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Authors:
  • RBRichard D. Baird
    Richard D. Baird
  • BHBegoña Bermejo de Las Heras
    Begoña Bermejo de Las Heras
  • MRManuel Ruiz-Borrego
    Manuel Ruiz-Borrego
  • CVChristos Vaklavas
    Christos Vaklavas
  • IMIrene Moreno
    Irene Moreno
  • Mafalda Oliveira
    Mafalda Oliveira
  • AAAnne Armstrong
    Anne Armstrong
  • NTNicholas Turner
    Nicholas Turner
  • JIJason Incorvati
    Jason Incorvati
  • CTChris Twelves
    Chris Twelves
  • ECEva Ciruelos
    Eva Ciruelos
  • EHErika Hamilton
    Erika Hamilton

Open Access
Publisher website
Google Scholar
  • 15 October 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.30363315
Abstract
Baseline characteristics and patient demographics for camizestrant in combination with abemaciclib, palbociclib, or ribociclib.
Keywords
  • GLOBALLY APPROVED
  • ADVANCED BREAST
  • BREAST CANCER
  • BASELINE CHARACTERISTICS
  • PATIENT DEMOGRAPHICS
  • COMBINATION
  • CAMIZESTRANT
  • TABLE
  • PALBOCICLIB
  • APPROVED
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.